Scalable, high throughput microfluidic platforms for tissue specific biomaterials development and tissue genesis

新型生物材料平台和新一代组织类似物生产方法的共同开发将为改进和更相关的方法提供必要的刺激，以增强病变或受损组织的修复或再生。这些成果将为澳大利亚和世界带来更快的新一代治疗产品上市时间。这些进步将对我们的医疗费用和所有澳大利亚人的生活质量产生重大影响。

The co-development of novel biomaterial platforms and new generation production methods for tissue analogues will provide the necessary stimulus for improved and more relevant methods of enhanced repair or regeneration of diseased or damaged tissues. These outcomes will result in faster time-to-market new generation therapeutic products for Australia and the world. These advances will have a significant impact on our healthcare costs and the quality of life for all Australians.